{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:26:23Z","timestamp":1793748383030,"version":"4.6.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23334-y","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:18:45Z","timestamp":1762885125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The serum platelet-to-lymphocyte ratio as a predictor of outcomes in bladder cancer patients: an updated meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"given":"Baining","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoyue","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongbao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"5","key":"23334_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC van Hoogstraten","year":"2023","unstructured":"van Hoogstraten, L. M. C. et al. Global trends in the epidemiology of bladder cancer: Challenges for public health and clinical practice. Nat. Rev. Clin. Oncol. 20(5), 287\u2013304 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"23334_CR2","first-page":"114","volume":"50","author":"A Ruggero","year":"2024","unstructured":"Ruggero, A., Clark, M., Lewkowski, A., Hurtado, R. & Tirado, C. A. Bladder cancer, a cytogenomic update. J. Assoc. Genet. Technol. 50(3), 114\u2013126 (2024).","journal-title":"J. Assoc. Genet. Technol."},{"issue":"1","key":"23334_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Primers. 9(1), 58 (2023).","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"16","key":"23334_CR4","doi-asserted-by":"publisher","first-page":"12596","DOI":"10.3390\/ijms241612596","volume":"24","author":"F Claps","year":"2023","unstructured":"Claps, F. et al. BCG-unresponsive non-muscle-invasive bladder cancer: Current treatment landscape and novel emerging molecular targets. Int. J. Mol. Sci. 24(16), 12596 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"23334_CR5","first-page":"e076743","volume":"384","author":"A Lopez-Beltran","year":"2024","unstructured":"Lopez-Beltran, A., Cookson, M. S., Guercio, B. J. & Cheng, L. Advances in diagnosis and treatment of bladder cancer. BMJ (Clinical research ed). 384, e076743 (2024).","journal-title":"BMJ (Clinical research ed)."},{"issue":"10061","key":"23334_CR6","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388(10061), 2796\u20132810 (2016).","journal-title":"Lancet"},{"issue":"3","key":"23334_CR7","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/iju.15338","volume":"31","author":"E Tomiyama","year":"2024","unstructured":"Tomiyama, E., Fujita, K., Hashimoto, M., Uemura, H. & Nonomura, N. Urinary markers for bladder cancer diagnosis: A review of current status and future challenges. Int. J. Urol. 31(3), 208\u2013219 (2024).","journal-title":"Int. J. Urol."},{"issue":"1","key":"23334_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12967-023-04056-z","volume":"21","author":"Z Tan","year":"2023","unstructured":"Tan, Z. et al. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. J. Transl. Med. 21(1), 223 (2023).","journal-title":"J. Transl. Med."},{"issue":"11","key":"23334_CR9","first-page":"2259","volume":"72","author":"MS Asghar","year":"2022","unstructured":"Asghar, M. S. et al. Inflammatory mediators as surrogates of malignancy. J. Pak. Med. Assoc. 72(11), 2259\u20132263 (2022).","journal-title":"J. Pak. Med. Assoc."},{"issue":"1","key":"23334_CR10","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","volume":"18","author":"MA Cupp","year":"2020","unstructured":"Cupp, M. A. et al. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med. 18(1), 360 (2020).","journal-title":"BMC Med."},{"issue":"15","key":"23334_CR11","doi-asserted-by":"publisher","first-page":"8002","DOI":"10.3390\/ijms22158002","volume":"22","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto, T., Kawada, K. & Obama, K. Inflammation-related biomarkers for the prediction of prognosis in colorectal cancer patients. Int. J. Mol. Sci. 22(15), 8002 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"23334_CR12","doi-asserted-by":"publisher","first-page":"575483","DOI":"10.3389\/fmolb.2020.575483","volume":"7","author":"X Tang","year":"2020","unstructured":"Tang, X. et al. Diagnostic value of inflammatory factors in pathology of bladder cancer patients. Front. Mol. Biosci. 7, 575483 (2020).","journal-title":"Front. Mol. Biosci."},{"issue":"2","key":"23334_CR13","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/cancers16020433","volume":"16","author":"E Desponds","year":"2024","unstructured":"Desponds, E. et al. immuno-transcriptomic profiling of blood and tumor tissue identifies gene signatures associated with immunotherapy response in metastatic bladder cancer. Cancers 16(2), 433 (2024).","journal-title":"Cancers"},{"issue":"4","key":"23334_CR14","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/cancers16040698","volume":"16","author":"R Pawaskar","year":"2024","unstructured":"Pawaskar, R. et al. Systematic review of preoperative prognostic biomarkers in perihilar cholangiocarcinoma. Cancers 16(4), 698 (2024).","journal-title":"Cancers"},{"key":"23334_CR15","doi-asserted-by":"publisher","first-page":"156389","DOI":"10.1016\/j.cyto.2023.156389","volume":"172","author":"M Sk\u00f3rzewska","year":"2023","unstructured":"Sk\u00f3rzewska, M. et al. Systemic inflammatory response markers for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer. Cytokine 172, 156389 (2023).","journal-title":"Cytokine"},{"key":"23334_CR16","doi-asserted-by":"publisher","first-page":"672499","DOI":"10.3389\/fendo.2021.672499","volume":"12","author":"E Giannetta","year":"2021","unstructured":"Giannetta, E. et al. Are markers of systemic inflammatory response useful in the management of patients with neuroendocrine neoplasms?. Front. Endocrinol. (Lausanne). 12, 672499 (2021).","journal-title":"Front. Endocrinol. (Lausanne)."},{"key":"23334_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3389\/fonc.2019.00757","volume":"9","author":"X Wang","year":"2019","unstructured":"Wang, X., Ni, X. & Tang, G. Prognostic role of platelet-to-lymphocyte ratio in patients with bladder cancer: a meta-analysis. Front. Oncol. 9, 757 (2019).","journal-title":"Front. Oncol."},{"key":"23334_CR18","first-page":"n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ (Clinical research ed). 372, n71 (2021).","journal-title":"BMJ (Clinical research ed)."},{"issue":"1","key":"23334_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","volume":"21","author":"N Liu","year":"2021","unstructured":"Liu, N., Zhou, Y. & Lee, J. J. IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 21(1), 111 (2021).","journal-title":"BMC Med. Res. Methodol."},{"issue":"1","key":"23334_CR20","first-page":"1","volume":"2","author":"J Peterson","year":"2011","unstructured":"Peterson, J., Welch, V., Losos, M. & Tugwell, P. J. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Res. Inst. 2(1), 1\u201312 (2011).","journal-title":"Ottawa: Ottawa Hospital Res. Inst."},{"issue":"6","key":"23334_CR21","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/JTO.0b013e31821b10ab","volume":"6","author":"H Barraclough","year":"2011","unstructured":"Barraclough, H., Simms, L. & Govindan, R. Biostatistics primer: what a clinician ought to know: hazard ratios. J. Thorac. Oncol. 6(6), 978\u2013982 (2011).","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"23334_CR22","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1080\/03610911003650383","volume":"39","author":"H Chen","year":"2010","unstructured":"Chen, H., Cohen, P. & Chen, S. How big is a big odds ratio? interpreting the magnitudes of odds ratios in epidemiological studies. Commun. Stat. Simul. Comput. 39(4), 860\u2013864 (2010).","journal-title":"Commun. Stat. Simul. Comput."},{"issue":"2","key":"23334_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jclinepi.2010.01.009","volume":"64","author":"MM Al Khalaf","year":"2011","unstructured":"Al Khalaf, M. M., Thalib, L. & Doi, S. A. Combining heterogenous studies using the random-effects model is a mistake and leads to inconclusive meta-analyses. J. Clin. Epidemiol. 64(2), 119\u2013123 (2011).","journal-title":"J. Clin. Epidemiol."},{"issue":"1","key":"23334_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CM9.0000000000002814","volume":"137","author":"C Zhai","year":"2024","unstructured":"Zhai, C. & Guyatt, G. Fixed-effect and random-effects models in meta-analysis. Chin. Med. J. 137(1), 1\u20134 (2024).","journal-title":"Chin. Med. J."},{"key":"23334_CR25","doi-asserted-by":"publisher","first-page":"585297","DOI":"10.3389\/fonc.2020.585297","volume":"10","author":"S Qian","year":"2020","unstructured":"Qian, S. et al. Is sCD163 a clinical significant prognostic value in cancers? a systematic review and meta-analysis. Front. Oncol. 10, 585297 (2020).","journal-title":"Front. Oncol."},{"issue":"1","key":"23334_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1186\/s12916-023-03199-6","volume":"21","author":"Y Wang","year":"2023","unstructured":"Wang, Y., Xu, C. & Zhang, Z. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in patients with glioma: A meta-analysis. BMC Med. 21(1), 486 (2023).","journal-title":"BMC Med."},{"issue":"2","key":"23334_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/bjc.2015.432","volume":"114","author":"B Bhindi","year":"2016","unstructured":"Bhindi, B. et al. Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. Br J. Cancer. 114(2), 207\u2013212 (2016).","journal-title":"Br J. Cancer."},{"issue":"8","key":"23334_CR28","doi-asserted-by":"publisher","first-page":"12891","DOI":"10.18632\/oncotarget.14179","volume":"8","author":"M Kang","year":"2017","unstructured":"Kang, M., Jeong, C. W., Kwak, C., Kim, H. H. & Ku, J. H. Preoperative neutrophil-lymphocyte ratio can significantly predict mortality outcomes in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Oncotarget 8(8), 12891\u201312901 (2017).","journal-title":"Oncotarget"},{"issue":"11","key":"23334_CR29","doi-asserted-by":"publisher","first-page":"749","DOI":"10.4111\/kju.2015.56.11.749","volume":"56","author":"SM Lee","year":"2015","unstructured":"Lee, S. M., Russell, A. & Hellawell, G. Predictive value of pretreatment inflammation-based prognostic scores (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio) for invasive bladder carcinoma. Korean J. Urol. 56(11), 749\u2013755 (2015).","journal-title":"Korean J. Urol."},{"key":"23334_CR30","first-page":"5799","volume":"10","author":"SY Mao","year":"2017","unstructured":"Mao, S. Y. et al. Prognostic value of preoperative systemic inflammatory responses in patients with non-muscle invasive bladder cancer undergoing transurethral resection of bladder tumor. Int. J. Clin. Exp. Pathol. 10, 5799\u20135810 (2017).","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"4","key":"23334_CR31","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1159\/000477405","volume":"93","author":"M Miyake","year":"2017","unstructured":"Miyake, M. et al. Integrative assessment of pretreatment inflammation-, nutrition-, and muscle-based prognostic markers in patients with muscle-invasive bladder cancer undergoing radical cystectomy. Oncology 93(4), 259\u2013269 (2017).","journal-title":"Oncology"},{"issue":"1","key":"23334_CR32","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41598-018-19146-y","volume":"8","author":"D Peng","year":"2018","unstructured":"Peng, D. et al. Prognostic significance of HALP (hemoglobin, albumin, lymphocyte and platelet) in patients with bladder cancer after radical cystectomy. Sci. Rep. 8(1), 794 (2018).","journal-title":"Sci. Rep."},{"issue":"10","key":"23334_CR33","first-page":"3027","volume":"22","author":"P Rajwa","year":"2018","unstructured":"Rajwa, P., \u017byczkowski, M., Paradysz, A., Bujak, K. & Bryniarski, P. Evaluation of the prognostic value of LMR, PLR, NLR, and dNLR in urothelial bladder cancer patients treated with radical cystectomy. Eur. Rev. Med. Pharmacol. Sci. 22(10), 3027\u20133037 (2018).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"11","key":"23334_CR34","doi-asserted-by":"publisher","first-page":"8537","DOI":"10.1007\/s13277-015-3613-x","volume":"36","author":"GM Zhang","year":"2015","unstructured":"Zhang, G. M. et al. Preoperative lymphocyte-monocyte and platelet-lymphocyte ratios as predictors of overall survival in patients with bladder cancer undergoing radical cystectomy. Tumour Biol. 36(11), 8537\u20138543 (2015).","journal-title":"Tumour Biol."},{"key":"23334_CR35","doi-asserted-by":"publisher","first-page":"642","DOI":"10.3389\/fonc.2018.00642","volume":"8","author":"HD Yuk","year":"2018","unstructured":"Yuk, H. D., Jeong, C. W., Kwak, C., Kim, H. H. & Ku, J. H. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in non-muscle invasive bladder cancer patients: initial intravesical bacillus calmette-guerin treatment after transurethral resection of bladder tumor setting. Front. Oncol. 8, 642 (2018).","journal-title":"Front. Oncol."},{"issue":"5","key":"23334_CR36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.4103\/njcp.njcp_399_22","volume":"26","author":"A Caglayan","year":"2023","unstructured":"Caglayan, A. & Horsanali, M. O. Can peripheral blood systemic immune response parameters predict oncological outcomes in patients with non-muscle-invasive bladder cancer?. Niger J. Clin. Pract. 26(5), 591\u2013598 (2023).","journal-title":"Niger J. Clin. Pract."},{"issue":"2","key":"23334_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s11255-023-03812-w","volume":"56","author":"R Kayar","year":"2024","unstructured":"Kayar, R. et al. Pan-immune-inflammation value as a prognostic tool for overall survival and disease-free survival in non-metastatic muscle-invasive bladder cancer. Int. Urol. Nephrol. 56(2), 509\u2013518 (2024).","journal-title":"Int. Urol. Nephrol."},{"issue":"6","key":"23334_CR38","doi-asserted-by":"publisher","first-page":"706","DOI":"10.21873\/cdp.10275","volume":"3","author":"C Karan","year":"2023","unstructured":"Karan, C. et al. Pretreatment PLR Is preferable to NLR and LMR as a predictor in locally advanced and metastatic bladder cancer. Cancer Diagn. Progn. 3(6), 706\u2013715 (2023).","journal-title":"Cancer Diagn. Progn."},{"issue":"3","key":"23334_CR39","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/03936155241261719","volume":"39","author":"X Wang","year":"2024","unstructured":"Wang, X., Zhang, S., Sun, Y., Cai, L. & Zhang, J. The prognostic significance of preoperative platelet-to-lymphocyte ratio and interleukin-6 level in non-muscle invasive bladder cancer. Int. J. Biol. Markers. 39(3), 255\u2013264 (2024).","journal-title":"Int. J. Biol. Markers."},{"issue":"4","key":"23334_CR40","first-page":"e59299","volume":"16","author":"MA Avc\u0131","year":"2024","unstructured":"Avc\u0131, M. A., Arslan, B., Arslan, O. & \u00d6zdemir, E. The role of thrombocyte\/lymphocyte ratio and aspartate transaminase\/alanine transaminase (De Ritis) ratio in prediction of recurrence and progression in non-muscle invasive bladder cancer. Cureus. 16(4), e59299 (2024).","journal-title":"Cureus."},{"issue":"18","key":"23334_CR41","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.21037\/atm-21-4097","volume":"9","author":"W Zhang","year":"2021","unstructured":"Zhang, W. et al. Development of nomograms related to inflammatory biomarkers to estimate the prognosis of bladder cancer after radical cystectomy. Ann. Transl. Med. 9(18), 1440 (2021).","journal-title":"Ann. Transl. Med."},{"key":"23334_CR42","doi-asserted-by":"publisher","first-page":"907485","DOI":"10.3389\/fsurg.2022.907485","volume":"9","author":"R Wu","year":"2022","unstructured":"Wu, R. et al. Prognostic value of platelet-to-lymphocyte ratio in non-muscle invasive bladder cancer patients: Intravesical bacillus calmette-guerin treatment after transurethral resection of bladder tumor. Front. Surg. 9, 907485 (2022).","journal-title":"Front. Surg."},{"key":"23334_CR43","doi-asserted-by":"publisher","first-page":"1189086","DOI":"10.3389\/fonc.2023.1189086","volume":"13","author":"X Yi","year":"2023","unstructured":"Yi, X. et al. The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model. Front. Oncol. 13, 1189086 (2023).","journal-title":"Front. Oncol."},{"key":"23334_CR44","doi-asserted-by":"publisher","first-page":"1101830","DOI":"10.3389\/fonc.2022.1101830","volume":"12","author":"C Wang","year":"2022","unstructured":"Wang, C., Jin, W., Ma, X. & Dong, Z. The different predictive value of mean platelet volume-to-lymphocyte ratio for postoperative recurrence between non-muscular invasive bladder cancer patients treated with intravesical chemotherapy and intravesical chemohyperthermia. Front. Oncol. 12, 1101830 (2022).","journal-title":"Front. Oncol."},{"issue":"5","key":"23334_CR45","doi-asserted-by":"publisher","first-page":"102144","DOI":"10.1016\/j.clgc.2024.102144","volume":"22","author":"A Salari","year":"2024","unstructured":"Salari, A. et al. Prognostic value of NLR, PLR, SII, and dNLR in urothelial bladder cancer following radical cystectomy. Clin. Genitourin Cancer. 22(5), 102144 (2024).","journal-title":"Clin. Genitourin Cancer."},{"key":"23334_CR46","doi-asserted-by":"crossref","unstructured":"Yilmaz \u0130\u00d6, De\u011fer M, Akdo\u011fan N, Aridogan I, Bayaz\u0131t Y, Urooncology VIJTBo. Prognostic values of inflammatory markers in patients with high-grade lamina propria-invasive bladder cancer. 2024;48.","DOI":"10.4274\/uob.galenos.2023.2023.2.1"},{"key":"23334_CR47","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-981-13-3681-2_2","volume":"91","author":"L M\u00fcller","year":"2019","unstructured":"M\u00fcller, L., Di Benedetto, S. & Pawelec, G. The immune system and its dysregulation with aging. Subcell Biochem. 91, 21\u201343 (2019).","journal-title":"Subcell Biochem."},{"key":"23334_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jcpa.2022.01.002","volume":"192","author":"SC Bulla","year":"2022","unstructured":"Bulla, S. C., Badial, P. R. & Bulla, C. Canine cancer cells activate platelets via the platelet P2Y12 receptor. J. Comp. Pathol. 192, 41\u201349 (2022).","journal-title":"J. Comp. Pathol."},{"issue":"1","key":"23334_CR49","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1186\/s40001-023-01342-w","volume":"28","author":"L Zhou","year":"2023","unstructured":"Zhou, L. et al. The critical role of platelet in cancer progression and metastasis. Eur. J. Med. Res. 28(1), 385 (2023).","journal-title":"Eur. J. Med. Res."},{"issue":"4","key":"23334_CR50","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens, S. T., Vledder, A., de Bruyn, M. & Nijman, H. W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 18(4), 842\u2013859 (2021).","journal-title":"Cell Mol Immunol."},{"issue":"1","key":"23334_CR51","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1186\/s12957-020-01952-2","volume":"18","author":"X Zhang","year":"2020","unstructured":"Zhang, X. et al. Clinicopathological and prognostic significance of platelet-lymphocyte ratio (PLR) in gastric cancer: An updated meta-analysis. World J. Surg. Oncol. 18(1), 191 (2020).","journal-title":"World J. Surg. Oncol."},{"key":"23334_CR52","doi-asserted-by":"publisher","first-page":"1578069","DOI":"10.3389\/fimmu.2025.1578069","volume":"16","author":"W Hu","year":"2025","unstructured":"Hu, W. et al. Elevated platelet-to-lymphocyte ratio predicts poor clinical outcomes in non-muscle invasive bladder cancer: A systematic review and meta-analysis. Front. Immunol. 16, 1578069 (2025).","journal-title":"Front. Immunol."},{"issue":"4","key":"23334_CR53","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4103\/2229-3485.167092","volume":"6","author":"P Ranganathan","year":"2015","unstructured":"Ranganathan, P., Aggarwal, R. & Pramesh, C. S. Common pitfalls in statistical analysis: Odds versus risk. Perspect. Clin. Res. 6(4), 222\u2013224 (2015).","journal-title":"Perspect. Clin. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23334-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23334-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23334-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:02:52Z","timestamp":1762891372000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23334-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23334"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23334-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"3 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39502"}}